Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOnyema Ogbuagu, Jason Flamm, Peter Ruane et al.|The Lancet HIV|2021Cited by 91
Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network CohortJuan Berenguer, Inmaculada Jarrín, Federico Pulido et al.|Clinical Microbiology and Infection|2021Cited by 50
Peak Bone Mass in Young HIV-Infected Patients Compared With Healthy ControlsEugènia Negredo, Bonaventura Clotet, Peré Domingo et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2013Cited by 35
Influence of Geographical Origin and Ethnicity on Mortality in Patients on Antiretroviral Therapy in Canada, Europe, and the United StatesM. John Gill, Inmaculada Jarrín, Margaret May et al.|Clinical Infectious Diseases|2013Cited by 34
Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015José Antonio Iribarren, Miguel Ángel von Wichmann, Rafael Rubio et al.|Enfermedades Infecciosas y Microbiología Clínica|2016Cited by 18